MiNK Therapeutics announced the presentation of preclinical data from MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer liver metastases. “Liver metastases, especially in MSS-CRC, have remained a critical challenge in cancer care and represent a setting where novel therapeutic approaches are urgently needed to improve outcomes for patients,” said Dr. Marc van Dijk, Chief Scientific Officer at MiNK. “These first-of-a-kind data underscore the unique potential of iNKT cells to overcome the refractory liver microenvironment. We are proud to partner with Agenus on these innovative models to aid the design of clinical studies that can evaluate the synergy of allogeneic iNKT cells and botensilimab/balstilimab to expand benefit for patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INKT:
- MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
- MiNK Therapeutics Strikes Convertible Note Deal with Agenus
- MiNK Therapeutics announces first patient dosed in Phase 2 study for agenT-797
- MiNK announces publication of results from Phase 1/2 study of agenT-797
- MiNK Therapeutics announces publication of case report on agenT-797